Mounjaro/Zepbound

Mounjaro/Zepbound

マンジャロとは

マンジャロは、GLP-1とGIPの"両方"に作用する「デュアル作動薬」です。週１回の皮下注射で、血糖コントロールと体重減少効果の両方が期待される新しいタイプの薬剤です。

ALL ITEMS

商品一覧

EFFICACY

Efficacy

The active ingredient "tirzepatide" works simultaneously on two hormones, GLP-1 and GIP, supporting both blood glucose control and weight reduction.

Lowers blood glucose

By promoting insulin secretion and suppressing glucagon secretion, it prevents rapid blood glucose spikes. With stable glucose control, it is expected to suppress the conversion of excess sugar into fat.

Sustains satiety

By slowing gastric motility and acting on the brain to suppress appetite, it prevents overeating and enables comfortable control of meal intake.

Improves fat metabolism

By regulating the function of fat cells, it makes it easier for accumulated body fat to be used as energy, leading to efficient weight loss.

*In Japan, this drug is approved only as a treatment for type 2 diabetes.

EVIDENCE

Medical evidence

In a clinical trial of Japanese patients with type 2 diabetes (SURPASS J-mono trial), the following results were reported:

  • HbA1c (blood glucose indicator) decreased by up to 2.8%
  • Body weight decreased by up to 10.7 kg

(Inagaki et al., 2022)
This was superior to the conventional GLP-1 receptor agonist (dulaglutide), suggesting a "synergistic effect" from acting on both GLP-1 and GIP.

Source: Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. et al. (2022). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology, 10(9), 623-633.

HOW TO TAKE

How to take

  • Dose
    ・The Mounjaro/Zepbound injector is a single-use type, one full pen per injection.
    ・Inject the prescribed dose (2.5mg–10mg) once a week.
  • Frequency
    ・Inject this medication once a week, on the same day of the week.
  • Injection method
    ・Self-inject at one of the following fat-rich sites:
    ・Thigh
    ・Abdomen
    ・Upper arm
    ・Shift the injection site by 2–3 cm each time. Repeated injection in the same spot may cause skin hardening.
  • Other
    ・If you miss a dose: if there are 3 or more days (72 hours) until the next dose, inject as soon as you notice and then resume on the originally scheduled weekday.
    ・If less than 3 days (72 hours) remain until the next dose, skip and inject on the next scheduled day.
    ・If you need to change the weekly injection day, leave at least 3 days (72 hours) between injections.
ADVERSE EFFECTS

Adverse effects

Digestive symptoms such as nausea, vomiting, diarrhea, constipation

Nausea and vomiting are especially likely during initial use.

Hypoglycemia (rare)

Strong hunger, cold sweat, tremors, dizziness, etc.

Acute pancreatitis (rare)

Fever, severe upper abdominal pain, persistent severe pain in the epigastric area or under the left ribs.

Cholecystitis (rare)

Fever, yellowing of skin or whites of eyes (jaundice), pain under the right ribs, etc.

Anaphylaxis (rare)

Whole-body hives, breathing difficulty, swelling of face or throat, etc.

If you experience any of the above symptoms (including pain or swelling at the injection site or fatigue), stop using immediately and consult a medical institution.

  • ※1 If you are allergic to ingredients in this drug, consult a doctor in advance.
  • ※2 If you have been diagnosed with diabetic ketoacidosis, diabetic coma, pre-coma, or type 1 diabetes, consult a doctor. This drug is contraindicated. Rapid treatment with insulin is required.
  • ※3 If you have planned surgery or a serious infection, consult a doctor. This drug is contraindicated; insulin-based glucose control is preferred.
  • ※4 If pregnant or breastfeeding, consult a doctor in advance. This drug is generally not recommended for pregnant women or women who may be pregnant. Weigh treatment benefits against breastfeeding to decide whether to continue or stop breastfeeding.
  • ※5 If taking other medications, consult a doctor. In particular, since this drug contains tirzepatide, it cannot be combined with other tirzepatide products such as Zepbound. Depending on the medication, hypoglycemia may occur.
  • ※6 This drug has other usage precautions. Receive a consultation and explanation from a doctor before use.
KEY INFORMATION ON OUR MEDICATIONS

About our medications

Unapproved medications, etc.This drug is approved by Japan's Ministry of Health, Labour and Welfare as a treatment for type 2 diabetes, but its efficacy/effects for obesity or weight loss are not approved.
Procurement routeThe medical institutions our clinic partners with purchase Mounjaro through domestic pharmaceutical wholesalers.
Availability of domestic drugs with the same ingredient/performanceA drug with tirzepatide as the active ingredient (Zepbound) is approved in Japan as an obesity treatment under certain conditions. However, Zepbound's indication is limited to specific obesity cases involving comorbid hypertension, dyslipidemia, or type 2 diabetes, and its use for cosmetic weight loss is not approved.
Safety information from overseasApproved by the US FDA and the European EMA as a treatment for type 2 diabetes and obesity.
Public relief system applicabilityThis drug is approved in Japan, but use outside the approved indication, usage, or dose, or use as part of private cosmetic treatment, may fall outside the scope of the Adverse Drug Reaction Relief System.